Topical Ruxolitinib Therapeutic Cheat Sheet
Ruxolitinib (OPZELURA) is a twice daily topical cream that is FDA approved for non-segmental vitiligo and mild to moderate atopic dermatitis1. JAK inhibitors are a class of drugs effective in treating a wide variety of inflammatory conditions. Initially only FDA approved for non-dermatologic conditions such as rheumatoid arthritis and ulcerative colitis, there is now strong evidence that JAK/STAT …
Ruxolitinib (OPZELURA) is a twice daily topical cream that is FDA approved for non-segmental vitiligo and mild to moderate atopic dermatitis1. JAK inhibitors are a class of drugs effective in treating a wide variety of inflammatory conditions. Initially only FDA approved for non-dermatologic conditions such as rheumatoid arthritis and ulcerative colitis, there is now strong evidence that JAK/STAT … Continue reading "Topical Ruxolitinib Therapeutic Cheat Sheet"
Infection by which of the following organisms is most likely to be present in the patient’s condition?
A. Cutibacterium acnes
B. Herpes simplex virus
C. Poxvirus
D. Staphylococcus aureus
E. Streptococcus agalactiae
F. Streptococcus pyogenes
To find out the correct answer and read the explanation, click here.
Brought to you by our brand partner
… 
Intravenous immune globulin (IVIG) is a concentrate of pooled immunoglobulins derived from plasma donors. Its unique mechanism of action expands the utility of the medication to a variety of conditions. We continue our series, Therapeutic Cheat Sheet, with a closer look at IVIG, which is FDA-approved for the treatment of dermatologic conditions including dermatomyositis, Kawasaki disease, ITP, and … 
Baricitinib (Olumiant®) is a once daily oral medication recently FDA approved for severe alopecia areata, which is defined as having a Severity of Alopecia Tool (SALT) score of 50 or higher.1 JAK inhibitors are a relatively new class of drug demonstrating efficacy and safety in a range of inflammatory skin disorders. Emerging studies have highlighted baricitinib’s effectiveness for conditions l … 
Next Steps in Derm, in partnership with ODAC Dermatology, Aesthetic & Surgical Conference, interviewed Dr. Shawn Kwatra, associate professor of dermatology at Johns Hopkins University School of Medicine. Watch and learn Dr. Kwatra’s tips for a workup in an itchy patient. Itch falls on the neuroimmune spectrum, so learn why it’s important to determine if a dermatological condition is to bl … 